Exact Sciences
Top Five Articles on 360Dx Last Week: Agilent Reorganizes; Guardant Health Awarded $292.5M; More
Last week, readers were most interested in a story about Agilent changing two of its three business organizations to accelerate growth.
The firm is engaging with regulators about its recently validated Ataraxis Breast test, which it hopes to make available for clinical use next year.
Exact Sciences Shares Rise on Unexpected Reimbursement Rate From CMS for Next-Gen Cologuard Test
The next-generation version of the Cologuard test received FDA approval last month and is expected to launch next year.
In an indirect comparison study by researchers in Germany, a fecal immunochemical test showed similar sensitivity and specificity as Exact Sciences' Cologuard Plus test.
The researchers used publicly available data from companies such as Guardant Health, Exact Sciences, and Geneoscopy to determine possible effects of blood-based tests.
Oct 1, 2024
360Dx Top 30 Inches up 1 Percent in September
Sep 3, 2024
360Dx Top 30 Ticks up 2 Percent in August
Jun 4, 2024
360Dx Top 30 Rises 3 Percent in May
Apr 1, 2024